Chalouhi CK, et al. - For the comparison of gadoxetic acid–enhanced MRI and performance of gadobenate dimeglumine–enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction, a retrospective cross-sectional study was conducted by the investigators which included 249 cirrhotic patients. Out of these paients, they assessed the unenhanced phase and the HBP of 131 gadobenate dimeglumine–enhanced MRI examinations (gadobenate dimeglumine group) and 127 gadoxetic acid–enhanced MRI examinations (gadoxetic acid group). The hepatobiliary phase obtained with gadoxetic acid–enhanced MRI was found to be of better quality, in patients with liver cirrhosis as compared to those with gadobenate dimeglumine–enhanced MRI, especially in patients sustaining model for end-stage liver disease score.